Skip to content
AKT Inhibition in Prostate Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium episode artwork

EPISODE · Sep 5, 2026 · 17 MIN

AKT Inhibition in Prostate Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

from Oncology Today with Dr Neil Love

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics: Tolerability of capivasertib and management of associated side effects — Question from Neeraj Agarwal, MD, FASCO (0:00) Case: A man in his early 70s with Type 2 diabetes presents with metastatic hormone-sensitive prostate cancer with widespread bone metastases and PTEN deficiency on next-generation sequencing and receives relugolix/darolutamide — Rana R McKay, MD, FASCO (8:39) CME information and select publications

Episode metadata supplied by the publisher feed · Published Sep 5, 2026

Embed this episode

Ready to play

AKT Inhibition in Prostate Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium

0:00 17:37

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Oncology Today with Dr Neil Love?

This episode is 17 minutes long.

When was this Oncology Today with Dr Neil Love episode published?

This episode was published on September 5, 2026.

Can I download this Oncology Today with Dr Neil Love episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!